MAPS no longer participating in bought-deal public offering
Rick Doblin
MDMA pioneer Rick Doblin will collaborate with Numinus Wellness Inc. as an unpaid strategic adviser, with the aim of expanding the availability of psychedelic therapy, Numinus announced on Feb. 14.
Doblin, the founder and president of the Multidisciplinary Association for Psychedelic Studies, or MAPS, will lend his expertise to help Numinus develop its MDMA-assisted therapy program.
“My hope in becoming an unpaid, non-exclusive Numinus strategic adviser is to accelerate our collective mission to expand access to psychedelic-assisted therapies,” said Doblin in a prepared statement. “I look forward to contributing to the evolution of MDMA-related training and care programs, ultimately advancing the standard of care in this transformative field.
The move comes on the heels of Numinus’ $6 million bought-deal public offering announced on Feb. 1. MAPS was initially expected to play a role in the deal, but Numinus said in the Feb. 14 announcement that the organization is no longer able to participate in the offering. Also bowing out is Integrated V.C., a venture fund that invests in various health and wellness-related companies.
Eight Capital, on behalf of a syndicate of underwriters including Stifel GMP agreed to purchase, on a bought-deal basis, 50 million units for $0.12 each.
Photo courtesy of the Multidisciplinary Association for Psychedelic Studies (MAPS)